Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch
Despite modern achievements in therapy of malignant melanomas new treatment strategies are welcomed in clinics for survival of patients. Now it is supposed that personalized molecular therapies for each patient are needed concerning a specificity of molecular alterations in patient's tumors. In...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-01-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1010660X15000439 |
| _version_ | 1827847213543325696 |
|---|---|
| author | Julija Mozūraitienė Kristina Bielskienė Vydmantas Atkočius Danutė Labeikytė |
| author_facet | Julija Mozūraitienė Kristina Bielskienė Vydmantas Atkočius Danutė Labeikytė |
| author_sort | Julija Mozūraitienė |
| collection | DOAJ |
| description | Despite modern achievements in therapy of malignant melanomas new treatment strategies are welcomed in clinics for survival of patients. Now it is supposed that personalized molecular therapies for each patient are needed concerning a specificity of molecular alterations in patient's tumors. In human melanoma, Notch signaling interacts with other pathways, including MAPK, PI3K-AKT, NF-kB, and p53. This article discusses mutated genes and leading aberrant signal pathways in human melanoma which are of interest concerning to their perspective for personalized treatment strategies in melanoma. We speculate that E3 ubiquitin ligases MDM2 and MDM4 can be attractive therapeutic target for p53 and Notch signaling pathways in malignant melanoma by using small molecule inhibitors. It is possible that restoration of p53-MDM2-NUMB complexes in melanoma can restore wild type p53 function and positively modulate Notch pathway. In this review we summarize recent data about novel US Food and Drug Administration approved target drugs for metastatic melanoma treatment, and suppose model for treatment strategy by targeting Notch. |
| first_indexed | 2024-03-12T09:26:20Z |
| format | Article |
| id | doaj.art-6289cbfc2dc34d978daad15f228a8d6e |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T09:26:20Z |
| publishDate | 2015-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-6289cbfc2dc34d978daad15f228a8d6e2023-09-02T14:10:22ZengMDPI AGMedicina1010-660X2015-01-0151313314510.1016/j.medici.2015.06.002Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of NotchJulija Mozūraitienė0Kristina Bielskienė1Vydmantas Atkočius2Danutė Labeikytė3National Cancer Institute, Vilnius, LithuaniaDepartment of Biochemistry and Molecular Biology, Vilnius University, Vilnius, LithuaniaNational Cancer Institute, Vilnius, LithuaniaDepartment of Biochemistry and Molecular Biology, Vilnius University, Vilnius, LithuaniaDespite modern achievements in therapy of malignant melanomas new treatment strategies are welcomed in clinics for survival of patients. Now it is supposed that personalized molecular therapies for each patient are needed concerning a specificity of molecular alterations in patient's tumors. In human melanoma, Notch signaling interacts with other pathways, including MAPK, PI3K-AKT, NF-kB, and p53. This article discusses mutated genes and leading aberrant signal pathways in human melanoma which are of interest concerning to their perspective for personalized treatment strategies in melanoma. We speculate that E3 ubiquitin ligases MDM2 and MDM4 can be attractive therapeutic target for p53 and Notch signaling pathways in malignant melanoma by using small molecule inhibitors. It is possible that restoration of p53-MDM2-NUMB complexes in melanoma can restore wild type p53 function and positively modulate Notch pathway. In this review we summarize recent data about novel US Food and Drug Administration approved target drugs for metastatic melanoma treatment, and suppose model for treatment strategy by targeting Notch.http://www.sciencedirect.com/science/article/pii/S1010660X15000439Notch pathwayp53 pathwayMDM2 E3 ubiquitin ligaseMDM4 E3 ubiquitin ligaseMelanoma |
| spellingShingle | Julija Mozūraitienė Kristina Bielskienė Vydmantas Atkočius Danutė Labeikytė Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch Medicina Notch pathway p53 pathway MDM2 E3 ubiquitin ligase MDM4 E3 ubiquitin ligase Melanoma |
| title | Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch |
| title_full | Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch |
| title_fullStr | Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch |
| title_full_unstemmed | Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch |
| title_short | Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch |
| title_sort | molecular alterations in signal pathways of melanoma and new personalized treatment strategies targeting of notch |
| topic | Notch pathway p53 pathway MDM2 E3 ubiquitin ligase MDM4 E3 ubiquitin ligase Melanoma |
| url | http://www.sciencedirect.com/science/article/pii/S1010660X15000439 |
| work_keys_str_mv | AT julijamozuraitiene molecularalterationsinsignalpathwaysofmelanomaandnewpersonalizedtreatmentstrategiestargetingofnotch AT kristinabielskiene molecularalterationsinsignalpathwaysofmelanomaandnewpersonalizedtreatmentstrategiestargetingofnotch AT vydmantasatkocius molecularalterationsinsignalpathwaysofmelanomaandnewpersonalizedtreatmentstrategiestargetingofnotch AT danutelabeikyte molecularalterationsinsignalpathwaysofmelanomaandnewpersonalizedtreatmentstrategiestargetingofnotch |